Jensen, M.-B. http://orcid.org/0000-0001-5348-3040
Pedersen, C. B.
Misiakou, M.-A.
Talman, M.-L. M.
Gibson, L.
Tange, U. B.
Kledal, H.
Vejborg, I.
Kroman, N.
Nielsen, F. C.
Ejlertsen, B. http://orcid.org/0000-0001-8761-714X
Rossing, M.
Funding for this research was provided by:
Novo Nordisk Fonden (NNF21OC0072287)
Article History
Received: 13 December 2022
Accepted: 17 May 2023
First Online: 31 May 2023
Competing interests
: C.B.P., F.C.N., H.K., I.V., L.G., M.A.M., M.L.M.T., N.K., U.B.T. reported no disclosures. B.E. reported institutional grants from Astra Zeneca, Eli Lilly, MSD, Novartis, Oncology Venture, Pfizer, Roche, and Samsung Bioepis. M.B.J. reported meeting expenses from Novartis and Advisory Board Novartis. M.R. reported personal fees from Glaxo Smith Kline and Astra Zeneca, and Advisory Board MSD.